Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a Composition of Matter patent for ONC201, the company’s lead development candidate, as well as for several other compounds of the imipridone family. This new patent, along with a Composition of Matter patent for ONC201 issued in the United States in March 2019 and an intention to grant from the European Patent Office issued in August 2019, gives Oncoceutics extensive coverage for ONC201 around the world.
Oncoceutics licensed this group of patents from The Scripps Research Institute in August 2019 to expand its already broad patent coverage of ONC201 and related compounds. With these new patents, Oncoceutics has more than 20 patents for ONC201 issued globally with 10 patents for ONC201 issued by the United States Patent Office.
“We are delighted that CNIPA has recognized ONC201 and our portfolio of novel compounds, called imipridones, and is reviewing the Composition of Matter patent in China,” said Martin Stogniew, Ph.D., Chief Development Officer at Oncoceutics. “Our company’s extensive patent estate provides Oncoceutics with almost 20 years of patent protection in major markets around the world.”
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “imipridones,” that selectively target G protein-coupled receptors for oncology. The lead compound, ONC201, is an orally active small molecule DRD2 antagonist, currently in late Phase II clinical trials for patients with advanced cancers, such as H3 K27M-mutant high-grade glioma. The company is supported by grants from NCI, FDA, The Al Musella Foundation, The Michael Mosier Defeat DIPG Foundation, The Cure Starts Now, and a series of private and public partnerships.